There are 2137 resources available
320P - Oligometastatic breast cancer incidence and clinical presentation at diagnosis: About 131 cases
Presenter: Jean Louis Lacaze
Session: E-Poster Display
Resources:
Abstract
321P - First-line treatment patterns in HR+/HER2- locally advanced or metastatic breast cancer in Europe
Presenter: Katie Lewis
Session: E-Poster Display
Resources:
Abstract
322P - Prognostic factors for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Analyses from PALOMA-3
Presenter: Hope Rugo
Session: E-Poster Display
Resources:
Abstract
323P - A retrospective study of evaluating the status and security of re-biopsy in advanced breast cancer
Presenter: Huimin Lv
Session: E-Poster Display
Resources:
Abstract
324P - What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL
Presenter: Anja Welt
Session: E-Poster Display
Resources:
Abstract
325P - Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study
Presenter: Bella Kaufman
Session: E-Poster Display
Resources:
Abstract
326P - Exploratory analysis of TreatER+ight: A Canadian prospective real-world observational study in HR+ advanced breast cancer
Presenter: Catherine Doyle
Session: E-Poster Display
Resources:
Abstract
327P - Treatment sequencing in HR+/HER2- locally advanced or metastatic breast cancer: A real-world retrospective study in France, Germany, Italy and Spain
Presenter: Katie Lewis
Session: E-Poster Display
Resources:
Abstract
328P - Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: A randomized, open-label, phase II clinical trial
Presenter: Shigehira Saji
Session: E-Poster Display
Resources:
Abstract
329P - Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials
Presenter: Sara Hurvitz
Session: E-Poster Display
Resources:
Abstract